The IIT model speed advantage is real, but the longer-term story is data accumulation. Running trials faster and earlier means generating patient data at a pace the US system structurally cannot match especially for rare diseases and early-phase experiments that would never clear FDA IND review at scale.
This feeds forward into medical AI in ways that are not fully appreciated yet. ByteDance Health, Baidu Health, and a dozen newer startups are training models on clinical datasets that dwarf what any Western health system has centralized access to. HIPAA-era fragmentation, institutional IRB silos, and restrictions on cross-hospital data sharing create training data deserts that Chinese developers simply do not face. DeepSeek medical reasoning being strongest on Chinese disease profiles is not a coincidence.
The inversion the author describes is the visible tip. The less visible story: every trial generates training data for the next generation of Chinese medical AI, compounding an advantage that the US regulatory framework actively prevents building.
Interesting. While speed & drive in addition to curiosity are key factors which propel the Chinese ecosystem forward, I always wonder what happens in those cases of false positives and erroneous outcomes which are always statistically present in this industry. We never hear how those are handled in China ? The bureaucratic processes in US developed over time at least give a clear answer when there are bad outcomes.
Nice to see some appreciation of "Chinese characteristics".
The IIT model speed advantage is real, but the longer-term story is data accumulation. Running trials faster and earlier means generating patient data at a pace the US system structurally cannot match especially for rare diseases and early-phase experiments that would never clear FDA IND review at scale.
This feeds forward into medical AI in ways that are not fully appreciated yet. ByteDance Health, Baidu Health, and a dozen newer startups are training models on clinical datasets that dwarf what any Western health system has centralized access to. HIPAA-era fragmentation, institutional IRB silos, and restrictions on cross-hospital data sharing create training data deserts that Chinese developers simply do not face. DeepSeek medical reasoning being strongest on Chinese disease profiles is not a coincidence.
The inversion the author describes is the visible tip. The less visible story: every trial generates training data for the next generation of Chinese medical AI, compounding an advantage that the US regulatory framework actively prevents building.
Interesting. While speed & drive in addition to curiosity are key factors which propel the Chinese ecosystem forward, I always wonder what happens in those cases of false positives and erroneous outcomes which are always statistically present in this industry. We never hear how those are handled in China ? The bureaucratic processes in US developed over time at least give a clear answer when there are bad outcomes.